Physician profile
Caesar John Cortopassi
NPI 1932125101
$1,842.80
in general payments reported to CMS, 2019-2025
24 companies · $16.02 in 2025
The $16.02 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $178 · 2021: $135 · 2022: $418 · 2023: $441 · 2024: $232 · 2025: $16.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $425.14 | 2022-2024 | Azstarys |
| Pfizer INC. | $216.04 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $194.21 | 2019-2024 | Jornay Pm |
| Sobi, INC | $128.95 | 2019-2023 | |
| Welch Allyn | $117.60 | 2021 | |
| Neos Therapeutics, Lp | $108.69 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $92.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $75.48 | 2022-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Kaleo, INC. | $67.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $59.79 | 2022-2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $46.93 | 2019-2023 | Bexsero |
| Sanofi Pasteur INC. | $42.33 | 2020-2023 | |
| Adlon Therapeutics L.P. | $41.80 | 2019-2020 | |
| Shire North American Group INC | $39.82 | 2019 | |
| Hologic Sales and Service, LLC | $31.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $29.19 | 2024-2025 | Qelbree |
| Verrica Pharmaceuticals INC. | $20.63 | 2024 | Ycanth |
| Mission Pharmacal Company | $18.54 | 2019 | |
| Tris Pharma INC | $18.52 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.46 | 2024 | |
| Mylan Pharmaceuticals INC. | $15.42 | 2019 | |
| Genentech USA, INC. | $11.86 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $11.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caesar Cortopassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.